Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment
Abstract Atezolizumab, a biotherapeutic monoclonal antibody directed against PD-L1, has been shown to be efficacious in multiple oncology indications. In clinical trials, a subset of patients developed anti-atezolizumab antibodies, necessitating the development of a neutralizing antibody (NAb) assay...
Сохранить в:
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SpringerOpen
2025-02-01
|
| Серии: | AAPS Open |
| Online-ссылка: | https://doi.org/10.1186/s41120-024-00105-z |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|